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ABSTRACT 
Chronic HIV-1 infection is characterized by progressive depletion of CD4+ T lymphocytes, 
persistent immune activation and ongoing viral replication, leading to a profound 
immunodeficiency state if left untreated with antiretroviral therapy. However, a small percentage 
of infected individuals are able to maintain durable control of HIV replication and stable CD4 
counts, in the absence of antiretroviral treatment (ART). This rare group of individuals are known 
as Elite Controllers (ECs) and represent evidence that control of infection without ART for years 
is possible, thereby providing an extraordinary insight into new vaccine and functional cure 
strategies. Despite extensive studies, the specific mechanisms by which ECs maintain control 
remain undefined. A better understanding of host factors that contribute to how ECs spontaneously 
control the infection is crucial for future therapeutic strategies.  
In Paper I, we showed that ECs possessed a richer gut microbiota compared to untreated 
HIV-infected individuals, and that several metabolic pathways were significantly different to 
untreated individuals. Specifically, the tryptophan catabolism pathway in ECs was very similar to 
healthy subjects, indicating a contributing factor for lower persistent immune activation usually 
observed in HIV-infected individuals. Our data suggest that the unique bacterial composition and 
metabolic profile of ECs may be involved in control of infection. Further, in Paper II, we used a 
modified antibody assay, LIPS, to perform antibody profiling against HIV-1 proteome in ECs. We 
found that LIPS detected a strong response against several HIV-1 fusion proteins in ECs compared 
to long-term treated individuals. Interestingly, the observed heterogeneity in antibody levels among 
ECs were not very different from untreated, viremic patients, indicating a non-homogenous patient 
group among ECs and a continuous viral expression with limited release of virus.  
By adapting a comprehensive analysis strategy of transcriptomics and targeted proteomics 
(Paper III), we demonstrated that more than 150 protein-coding genes and 33 soluble factors were 
differentially expressed in ECs compared to untreated patients. In particular, CXCR6 and SIGLEC1 
(associated with viral entry and formation) were downregulated in ECs. Also, PD-1, an inhibitory 
receptor associated with T cell exhaustion, was significantly elevated in untreated vs both ECs and 
healthy subjects. The observed difference between ECs and untreated patients in molecular 
pathways regulating apoptosis, inflammation and cellular differentiation, suggests they play a 
synergistic role in HIV control. To further understand the differences in inhibitory receptor 
expression related to spontaneous HIV control, we assessed the expression of inhibitory molecules 
associated with T cell exhaustion on CD4+ T cells (Paper IV). We observed that ECs maintain a 
co-expression pattern of inhibitory receptors similar to healthy subjects and significantly different 
to both treated and untreated patients. We found that ECs harbor a “healthy” state of inhibitory 
receptor expression on CD4+ T cells that might play part in maintenance of their control status.   
In summary, this thesis describes a comprehensive analysis of important immune factors that 
is associated with natural control of HIV infection in ECs. The multidisciplinary approach has 
provided a better understanding for the complexity of spontaneous HIV control and possible future 
therapeutic interventions. 
 
 
 
  
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Infektion med humant immunbristvirus (hiv) har orsakat otroliga katastrofer under de senaste 
40 åren världen har känt till viruset. Infektionen och dess utveckling av sjukdomen AIDS har 
kostat flera miljoner människor deras liv och idag lever närmare 37 miljoner med hiv. Det finns 
effektiva bromsmediciner som möjliggör att en infekterad person kan leva ett relativt bra liv, 
men lång ifrån alla har tillgång till dessa mediciner. Det behövs ett botemedel mot hiv och 
enorma insatser har gjorts i försök att hitta ett vaccin som skyddar mot hiv, dock utan framgång. 
Det finns en väldigt liten grupp hiv-infekterade personer som lyckas hålla hivinfektionen i 
schack, dvs de har omätbara virus nivåer och deras immunförsvar mår relativt bra, utan att de 
behöver bromsmediciner. Kort sagt, dessa unika elite kontroller är ett bevis på att man kan 
kontrollera infektionen utan mediciner och inte utvecklar AIDS. Studerandet av elite kontroller 
kan ge en otrolig insyn på vilka underliggande biologiska mekanismer som ger upphov till 
denna naturliga kontroll av infektion. Denna avhandling hade som syfte att försöka förstå den 
immunologiska aspekten av kontroll, detta genom att studera T celler, antikroppsnivåer, 
tarmfloran och immunaktivering samt gen- och protein uttrycket hos 19 identifierade elite 
kontroller i Sverige. I studie I fann vi att elite kontroller har en rik tarmflora med en unik 
bakteriesignatur som skiljde sig avsevärt från andra hivinfekterade, men var väldigt lik icke-
infekterade (”friska”) personer. Olika bakteriegrupper var antingen mer frekventa eller nästan 
obefintliga hos elite kontroller, och dessa bakteriegrupperna hade ett statistik samband med 
immunaktivering. Vi såg även att ämnesomsättningsprofilen skiljde sig från elite kontroller och 
friska samt hivinfekterade, vilket tyder på att tarmfloran spelar en viktig roll i kontrollen av 
viruset. Vidare undersökte vi antikroppsnivåer mot olika hivproteiner hos elite kontroller 
(studie II) och fann att nivåerna varierade avsevärt bland dem. Nivåerna var högre hos elite 
kontrollerna än hos behandlade hivpatienter och lika de som är obehandlade med höga 
virusnivåer. Detta tyder på en underliggande, lågt puttrande virusreplikation samt heterogenitet 
bland elite controller. I studie III tillämpades en övergripande analysstrategi för att undersöka 
gen- och proteinuttrycket. Mer än 150 proteinkodande gener och 33 lösliga komponenter av 
immunsystemet var uttryckt annorlunda hos elite kontroller än hos obehandlade hivpatienter. 
Specifikt CXCR6 och SIGLEC1, som är molekyler associerade med hur hiv tränger in i cellen 
och cellformation, var nedreglerad hos elite kontroller. De signifikanta skillnaderna i 
molekylära processer som reglerar celldöd, inflammation och celldifferentiering tyder på att de 
samspelar för att behålla viruskontrollen i dessa individer. Slutligen så undersökte vi konceptet 
med ”T cells utmattning” genom att mäta uttrycket av inhibitoriska receptorer på CD4+ T 
cellerna (studie IV) och fann att uttrycket av TIGIT, CTLA-4 och PD-1 var lika mellan elite 
kontroller och friska individer, och olika gentemot välbehandlade och obehandlade 
hivpatienter. Elite kontroller har en ”frisk repertoar” av CD4+ T celler som kan spela en roll i 
att hålla viruset i schack. Sammanfattningsvis så visar studierna i denna avhandling att elite 
kontroller har flera olika parametrar som definierar deras kontroll status och att de mycket 
troligtvis samspelar i denna kontroll. Att fortsätta studera dessa unika elite kontroller är av 
ytterst vikt för att i framtiden kunna översätta resultat till ett eventuellt vaccin mot hiv.    
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1 INTRODUCTION 
Ever since the discovery of the human immunodeficiency virus type 1 (HIV), tremendous 
efforts have been made in order to diminish the epidemic that has caused the death of millions 
of people and is presently still affecting over 38 million individuals (1). Antiretroviral treatment 
(ART) effectively suppresses viral replication and increases peripheral CD4+ T cell counts, the 
main target cells, resulting in dramatic decrease of disease progression and AIDS-related 
morbidity (2,3). However, ART is not curative and better strategies for cure are required. Given 
that a preventive vaccine or complete virus eradication (sterilizing cure) is most unlikely in a 
near future, focus has instead shifted towards a functional cure; a state of durable control of 
viral replication and remission from HIV symptoms in the absence of ART without achieving 
complete eradication of the virus. A very small fraction of HIV-1 infected individuals are able 
to control viral replication and maintain stable CD4 counts for several years without ART (4-
6). These Elite Controllers (ECs) function as a natural model for functional cure and the 
importance of study the underlying factors of control in these subjects is essential.         
This thesis aims to investigate underlying factors associated with spontaneous HIV control, 
mainly immunological factors and parameters that could contribute to the understanding of 
how natural control can be achieved. We have studied immunological aspects of viral control 
in the unique EC cohort. The studies have included investigating the impact of the human gut 
microbiota in HIV infection and correlating immune activation, antibody profile against HIV, 
a comprehensive analysis of host protein profile and T cell exhaustion. This broad approach 
has given us knowledge about parameters involved in spontaneous viral control in ECs.    
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2 BACKGROUND 
2.1 THE HUMAN IMMUNODEFICIENCY VIRUS 
2.1.1 Discovery and origin of HIV 
The early 1980s mark the period of when the world became aware of HIV as the causative 
agent of acquired immune deficiency syndrome (AIDS) (7). AIDS was characterized by severe 
immunosuppression and opportunistic infections such as pneumonia and Kaposi’s sarcoma, 
and more evident in the men who have sex with men community (8). Although the epidemic 
had already started to gain some global attention some years prior to that, it was not until 
researchers declared that a retrovirus was causing pathological syndromes including AIDS 
that the epidemic got world attention. The discovery of HIV, or at the time of the finding 
named human T-cell leukemia virus (HTLV), granted researchers the Nobel Prize in 
Physiology or Medicine in 2008 (9).  
The majority of HIV infections are caused by HIV type 1 (HIV-1). The less virulent HIV type 
2 (HIV-2), which is more prevalent in West Africa, has a poor transmission capacity and 
infection rate (10,11). Both HIV-1 and HIV-2 have their origin from the simian variant of HIV, 
termed simian immunodeficiency virus (SIV), that primarily infects non-human primates that 
function as a natural host to SIV (12). Extensive phylogenetic studies have demonstrated that 
SIV very likely has been present in non-human primates, such as chimpanzees, for over 32,000 
years and have been transmitted to humans through several, independent introductions (13-15). 
Interestingly, SIV does not typically cause pathogenic events despite high levels of virus 
replication in their natural host, sooty mangabeys. However, when present in a non-natural 
host, such as rhesus macaques, SIV usually causes immunodeficiency and increased immune 
activation, events that are similar to AIDS in HIV-1 infection (16,17). In this thesis, the usage 
of the term “HIV” refers to HIV-1, unless otherwise specified.  
2.1.2 Viral structure and life cycle 
HIV is an approx. 100 nm large lentivirus belonging to the retrovirus family. The word “lente” 
is Latin for “slow” and implicates the slow disease progression and long incubation time upon 
infection with the virus. Common for HIV and all retroviruses is the cone-shaped capsid 
comprising of the viral protein p24. The capsid contains two copies of positive-sense single-
stranded RNA genome (about 9 kilobase pair long) which encodes three polyproteins; Gag, Pol 
and Env. The Gag proteins (matrix, capsid, nucleocapsid and p6) and Env proteins (surface 
molecules gp120 and gp41, located on the outer surface on the virus) are structural components 
that build up the virus. The Pol proteins reverse transcriptase (RT, present in all retroviruses), 
integrase and protease are enzymes vital for the viral replication cycle. Of particular importance 
is the RT, it transcribes the viral RNA genome into a DNA strand. In addition, accessory 
proteins are found which contribute to the assembling of a mature virus particle and are 
important for immune evasion (Vif, Vpr, Vpu and Nef), as well as Tat and Rev that provide 
gene regulatory functions (18).  
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HIV enters the target cell, mainly CD4+ T cells, via conformational binding of Env proteins 
to cell surface receptor CD4 and co-receptors (CCR5 and CXCR4). Blockage of the co-
receptors has been extensively studied as therapeutic interventions. Also, some individuals 
have a natural 32-base-pair deletion within the coding region of the CCR5 gene (CCR5D32), 
resulting in a non-functional receptor that does not support fusion of virus to the cell (19). 
The basic aspects of the HIV replication cycle are shown in figure 1. HIV harbors a huge 
capacity of replication dynamics and possesses a high mutation rate as RT is prone to making 
numerous errors per genome during just one replication cycle, in addition to error-making 
during the transcription of DNA to RNA (20,21). The rapid evolution of HIV, in combination 
with the large number of virions being produced, makes it a difficult target for an effective 
vaccine and provides an effective way to evade drug therapy and immune surveillance.  
 
 
Fig 1. Key aspects of the HIV life cycle. Reprinted with permission (22).  
2.1.3 Transmission and course of infection 
HIV is a blood-borne infectious agent that targets cells of the immune system. HIV enters the 
host via body fluids as both free infectious particles and infected cells, and mainly through 
blood, genital fluids and breast milk. The routes of transmission include sexual contact (hetero- 
and homosexual intercourse), injection through drug use (e.g. the usage of shared needles), 
maternal transmission (mother-to-child during pregnancy, delivery and breast feeding) and 
medical interventions where blood products are transfused. Although the HIV epidemic 
initially was labeled as a “disease among homosexuals” and more prevalent within the gay 
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communities, reports from UNAIDS declare that most new infections occur among young 
women, through heterosexual transmission (1,23).    
Following infection, the clinical course of disease progression differs substantially among 
individuals. Briefly, the infection can be divided into two phases; the acute phase which is then 
followed by the chronic, clinically “latent” phase. In cases where ART is not available or 
ineffective, a third phase is included during which the infected individual develops AIDS. The 
acute phase occurs one-three weeks after initial exposure to the virus and is in a subproportion 
hallmarked by symptoms, frequently similar to influenza. It is during the acute phase as the 
virus enters lymph nodes and starts replicating vigorously, establishing itself in vital cells 
within lymphoid organs. A strong HIV-specific immune response is initialized, resulting in 
lowering the viremia substantially and entering the chronic phase of the infection. The chronic 
phase, which can last a few months up to several years, is generally clinically asymptomatic. 
However, HIV still continues to replicate in CD4+ target cells inside lymph nodes and the 
beginning of a vicious cycle where the immune system kills virus in the blood, replenishes 
infected CD4+ T cells and maintains the accompanied immune activation, takes place (24,25). 
In the events of AIDS, the infected individual has reached a state where the immune system 
has deteriorated and no longer can maintain the infection. Opportunistic infections arise, where 
bacterial and other infectious agents seize the chance as the individual no longer has a standing 
immune defense (26).       
2.1.4 HIV persistence 
ART has indeed changed HIV infection from being considered a disease with a death sentence 
to a chronic condition that is considerably manageable. There are several different drugs that 
target different steps in the viral replication cycle; entry inhibitors blocking the binding of virus 
to surface receptors, fusion inhibitors that block the fusion of viral and cellular membrane and 
inhibitors of viral enzymes integrase, protease and RT. Although ART significantly improves 
the management of HIV infection, ART is not curative. The stage of HIV where it remains 
hidden from an effective immune response as well as drugs, has been entitled as latent. The 
term “cellular latency” indicates long-lived, resting, memory CD4+ T cells that harbor HIV 
provirus integrated into the host’s DNA (27-29). The provirus is not actively replicating and 
immunological inert, making it difficult for ART and the HIV-specific immune response to 
target those cells. Another difficulty with the resting CD4+ T cells containing viral reservoir is 
the “sanctuary sites” that shelter these cells. The sites can be located throughout the body in 
locations such as the central nervous system (CNS), lymph nodes, gut-associated lymphoid 
tissues (GALT) and genital tract, and is not easily accessible for ART or a HIV-specific 
immune response (30). While work by Chomont and colleagues identified that central- and 
transitional memory T cells (TCM and TTM) serve as the major cellular reservoirs for HIV in 
blood, the latest reservoir research has also focused on sanctuary sites in lymphoid organs (31). 
Recent work has particularly established that T follicular helper (Tfh) cells in lymph nodes 
serve as a major component of the HIV reservoirs. Interestingly, work from Louis J. Picker’s 
lab has demonstrated that B cell follicles, the site where Tfh cells are present, are a sanctuary 
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site for productive and persistent SIV replication. These data suggest that the B cell follicles 
could function as an immune-privileged barrier where an effective immune response cannot 
gain access (32).  
HIV persistence under ART is indeed a huge obstacle to overcome when aiming for eradication 
of the virus. Latency is established just days after initial infection and the formation of stable 
viral reservoirs in resting memory CD4+ T cells might even occur before the individual 
discovers being infected (33). Some suggestions to target newly-infected cells with ART early 
during acute infection, in order to prevent establishment of viral reservoirs, is a difficult 
scenario as many individuals do not seek care until the symptoms arise later. In settings with 
limited and/or inadequate access to ART, this is even a more difficult issue. The challenges of 
eliminating HIV reservoirs is in sorts a game of hide-and-seek; one must understand exactly in 
which sheltered compartments of the body the HIV hides and by what means to eradicate it.  
2.2 CONTROL OF HIV INFECTION 
Tremendous efforts have been made the past 30 years to find measures against the HIV 
epidemic (34), however, progress towards a preventative vaccine has been slow, not to 
mention a great share of disappointments and limited success. The highly noted STEP HIV 
vaccine trial (also known as HVTN 502 or Merck V520-023), used an adenovirus-vector-
based vaccine to induce a HIV-specific cell-mediated immunity in 3’000 non-infected 
subjects. However, the trial failed and a higher proportion of vaccinated subjects contracted 
HIV infection compared to non-infected individuals (35). As already mentioned, one major 
obstacle in inducing HIV-specific immunity and eradication of the virus, besides from 
genetic variability of viral proteins to escape immune surveillance, are the HIV latent 
reservoirs. Several therapeutic approaches towards a sterilizing cure, a complete eradication of 
persistent virus in the body, has been in the pipe-line and a main approach has been the “shock 
and kill” strategy to target latent reservoirs (36). The approach involves luring out latent HIV 
by reactivation of memory CD4+ T cells which will then induce the reactivated, infected cells 
into apoptosis and immune clearance. Meanwhile, the non-infected cells stay protected with 
ART. Reactivation of cells has been shown to be effectively mediated by histone deacetylase 
(HDAC) inhibitors, an epigenetic drug that induces expression of integrated provirus (37). 
However, a study published by Rasmussen et al demonstrate that although the HDAC inhibitor 
panobinostat disrupts HIV latency, it does not fully reduce the number of latent infected cells, 
once again showing the difficulties in eradicating latently infected cells (38).  
Given that a preventive vaccine or sterilizing cure is unlikely in a close future, focus has instead 
shifted towards a functional cure; a state of durable control of viral replication and remission 
from HIV symptoms in absence of ART, without achieving complete eradication of the virus. 
One case of functional cure has been achieved in the Berlin patient, a HIV-infected male who 
received a stem-cell transplantation from a CCR5D32 donor (39). First believed to have 
achieved complete elimination of the virus in the Berlin patient, Burbelo et al showed low 
levels of antibody response against RT, gp41and TAT in serum, indicating a unique stability 
of HIV proteins despite intervention (40). Another case of functional cure was the 
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“Mississippi baby”, an infant subjected to mother-to child transmission as the mother did not 
obtain treatment during the pregnancy. ART was initiated only 30 hours after birth and 
remained so for 18 months, in hope that the viral reservoirs had not been established due to 
early treatment. However, after almost two years without ART and no observed virus levels, 
viral rebound occurred in the child (41,42). Data from the Mississippi baby case and other 
similar ones, clearly demonstrate that early ART may restrict viral reservoirs but not eradicate 
them (43).  
2.2.1 Elite Controllers- a model of functional cure 
In 2010, Migueles et al reviewed the clinical features of nonprogressive HIV infection where 
they described the clinical course of two cases with known HIV seropositive status since 
several years back. Both had been ART-naïve and maintained stable CD4 counts as well as 
undetectable virus levels (44). Remarkably, a very small subset of HIV-infected individuals is 
able to control viral replication below detection limits and maintain stable CD4 cell counts for 
several years throughout infection in the absent of ART. This spontaneous and sustained 
control of HIV infection represents a very rare and distinct phenotype among HIV-infected 
subjects termed HIV controllers or ECs, and function as a natural model for functional cure (4-
6). The identification of infected subjects that remained AIDS-free, ART-naïve and with high 
and stable CD4 count has been present since mid 1990s and was then termed long-term 
nonprogressors (LTNPs) (45-49). Techniques for CD4 determinations came before HIV-RNA 
quantification in blood was available. LTNPs have been subjected for studies since the early 
nineties and has, in Professor Sönnerborg’s research group at Karolinska Institutet alone, earlier 
resulted in two theses (50,51). When viral load testing was introduced in the 1990s, it could 
initially only measure down to 1000 copies/ml. The sensitivity has gradually improved and 
today, most routine tests can measure down to 20 copies/ml. Thus, upon the introduction of 
viral load testing it became apparent that the majority of LTNPs were not able to control viral 
replication despite high CD4 counts and that this group contained in fact an even smaller 
subgroup. These “true” LTNPs, or ECs, exhibited the same criteria as LTNPs as well as being 
able to maintain undetectable plasma viral load (by standard clinical assays) for prolonged 
periods of time (52,53). However, the definition of ECs has been shown to be somewhat more 
complicated than expected and there is a discrepancy in terminology and inclusion criteria (44). 
ECs are extremely rare and the prevalence among the HIV-infected population is poorly 
defined. Hubert et al demonstrated that only one subject of 330 enrolled HIV patients (0.3%) 
presented a viral load below 20 copies/ml (54). Another study by Lambotte et al demonstrate 
that 15 of 1551 patients (<1%) were defined as HIV controllers. Although there is no exact 
number, most studies demonstrate that ECs constitutes less than 1% of the HIV-infected 
population (55,56).  
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Fig 2. Diagram showing the viral load events of HIV infection. Red line indicates the clinical course of an 
untreated, chronic disease progression while dotted blue line represent the typical decline in viral load, weeks 
after infection, observed in ECs. Photo by courtesy of Son Nguyen.    
As mentioned, ECs are poorly defined and studies are difficult to compare due to the 
heterogeneity in study labeling, study design and lengths of follow up (57-59). The basis of 
inclusion criteria, e.g. number of years as HIV seropositive, opportunistic infections, CD4 
counts, HIV RNA levels etc., varies greatly between different EC cohorts (44,60). Even the 
labeling of ECs or HIV controller differs which contributes to the difficulties of a clear 
definition. The HIV controller cohort (n=19 subjects) from the French National Agency for 
Research on AIDS (ANRS) is stringent with duration of HIV infection, >10 years, and no 
opportunistic infections among their controllers while less stringent on levels of plasma viral 
load for the enrolled subjects (<400 copies/ml). The levels of CD4 counts among the ECs is 
not encountered (55,61). This is not consistent with for example the Elite Suppressor cohort 
from the Ragon Institute in Boston (n= 66 subjects), that only included subjects that maintain 
HIV plasma levels below 50 copies/ml and does not encounter CD4 counts nor number of 
opportunistic infections (62). On the other side of the spectrum is the LTNP-cohort from 
National Institute of Allergy and Infectious Diseases (NIAID), that has identified 63 HIV-
infected subjects as controllers with emphasize on stable, non-declining CD4 counts, HIV RNA 
plasma levels below 50 copies/ml and without ART or any opportunistic infections (63). Some 
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suggest that one must take into account the virologic status (eg. transient of persistent low level 
viremia) of ECs in order to decrease the heterogeneity among cohorts (64).   
During later years, attempts have been made to standardize the definition. The International 
HIV Controllers Consortium has established the following criteria for ECs enrollment; HIV-
positive for more than one year (determined with standard serological determination), 
minimum three consecutive HIV RNA determinations below 75 copies/ml during this time 
period, while ART-naïve and AIDS-free (65). The Concerted Action on SeroConversion on 
AIDS and Death in Europe collaboration (CASCADE), part of the EuroCoord European 
network that collects HIV cohort collaboration, suggests that ECs are defined by either of two 
criteria; 1) HIV positive status for more than one year with minimum three consecutive HIV 
RNA determinations below 75 copies/ml during this time period AND all previous HIV RNA 
levels below 1000 copies/ml, or 2) HIV positive status for more than ten years with minimum 
two consecutive HIV RNA determinations, ≥90% of which are below 400 copies/ml (60). This 
joint effort to standardize the EC definition could indeed contribute to improve the observed 
heterogeneity that is so commonly observed among ECs. 
 
2.3 MECHANISMS OF CONTROL 
Upon the introduction of viral load testing in the 1990s, when it became apparent that some 
HIV-infected subjects were able to naturally control the virus infection and maintain stable 
CD4 counts, it was initially thought that these individuals had been infected with a defective 
or attenuated virus which contributed to their control status but this was early proven to be 
exceptions (66,67). Epidemiological factors such as gender, ethnic background and mode of 
infection appears to have little impact on whether an individual develop EC status (44).  
Research has established that the mechanism of control is very likely multifactorial; several 
different factors in combination contribute to control in different ECs as no infected subjects 
possess the same mechanism of control, indicating that ECs are a heterogeneous population 
(65,68). Collectively, the factors of natural control can roughly be divided into viral genetics 
(viral proteins and enzymes), host genetics and host immune response (innate and adaptive 
immunity). One cannot emphasize enough the importance of understanding the many different 
factors of spontaneous control in ECs as such findings can provide critical information for 
future vaccine and functional cure strategies.   
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Fig 3. Multifactorial causes of spontaneous HIV control in ECs.   
2.3.1 Viral genetics 
As mentioned earlier, the initial suggestion for the underlying mechanism of control observed 
in ECs, was that these individuals had been infected with a defective virus. The non-replication-
competent virus was believed to cause the low levels of viremia as the virus was not capable 
of reaching full viral potential. Indeed, infection with defective or attenuated virus, e.g. 
mutation and deletion in key functional and accessory HIV genes has been observed in long-
term nonprogression or EC (69-72). The most noted case of EC and infection with a defective 
virus is The Sidney Blood Bank cohort which comprises eight subjects who all had been 
infected with an attenuated, Nef/long terminal repeat-deleted strain virus from one single blood 
donor. Five of these subjects were subjected to long-term and adequate follow-up and all of 
them, including the donor, remained asymptomatic for 14-18 years post infection, without any 
treatment. Noteworthy, one infected subject died five years after infection at age 22, much 
likely due to causes related to HIV (73,74). Furthermore, studies of whole-genome sequencing 
of the virus derived from ECs have revealed impairment of viral strains. Functional attenuation 
of Env, Gag, Pol and Nef genes was described to result in reduced efficiency of cell entry and 
replication capacity (75-78).  
Although data demonstrate the presence of defective HIV in ECs, attenuated virus is present in 
only a small fraction of ECs, and most subjects harbor fully pathogenic and replication-
competent virus (79,80). One study, published by Bailey et al, demonstrated that an infected 
individual, who developed progressive disease, had been infected by a person who instead had 
developed EC status (81). Analysis of virus isolate from both individuals revealed replication-
competent virus that can cause progressive disease, similar to findings published elsewhere 
(82). Thus, decreased HIV function may be a hallmark of EC phenotype rather than the cause 
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of it. Viral factors and reduced fitness of HIV could play a small contributing factor to achieve 
control but the main contributor is likely host genetic and effective immunity in ECs.  
2.3.2 Host genetics 
Host genetic factors soon became the subject of research to understand control in ECs. An 
overrepresentation of certain human leukocyte antigen (HLA) alleles was observed among 
ECs. HLA genes encodes the major histocompatibility complex (MHC) proteins, expressed on 
the surface on all cells and is crucial for effective immune response. MHC proteins are 
responsible for presenting peptides from both intracellular and extracellular pathogens to 
immune cells and thus eliciting a functional immune response in order to clear the infection. 
Out of the two classes of MHC, class I is expressed on all cells and present intracellular 
pathogens, eg. viruses, for recognition by CD8+ T cells and effective clearance by cytotoxic T 
cells (CTLs). MHC class I is further subdivided into the classical, highly polymorphic HLA-
A, HLA-B and HLA-C, and the nonclassical, less polymorphic HLA-E, HLA-F and HLA-G. 
Genetic variations in HLA alleles has been observed with different disease progression. Large 
GWAS-studies have independently identified single-nucleotide polymorphism in both HLA-B 
and HLA-C alleles that is associated with host viral control as well as lack of control (83-85). 
“Protective” alleles, in particular HLA-B*57 but also HLA-B*27, HLA-B*13 and HLA-
B*58:01, are expressed in over 60% of the ECs compared to approximately 40% among 
infected subjects with rapid disease progression (44,62,86). In contrast, HLA-B*35 is 
associated with a more rapid disease progression towards AIDS-defining conditions (87,88). 
HLA-DRB1, belonging to MHC class II, has also been associated with HIV control. In a 
cohort of HIV controllers (defined as viral load below 2000 copies/ml) and progressors (over 
10’000 copies/ml), HLA-DRB1*15:02 was significantly associated with low viremia while 
HLA-DRB1*03:01 was linked with high viremia (89).     
Another noted polymorphism of host genetics has been observed in the CCR5 and CCR2 gene, 
which encodes co-receptors for cell-mediated entry by HIV. A 32-base pair deletion in the 
CCR5 gene mediates resistance to infection by R5 tropic virus, and is associated with delayed 
disease progression and lower viral load (83,90,91). However, the prevalence of CCR5D32 
among healthy populations appears neither different nor enriched in HIV controller cohorts 
(55,62,86,92). Noteworthy to mention is that some ECs do not express any of the protective 
alleles and the opposite, a fraction of ECs that do express protective alleles, still develop 
progressive disease after a certain time period. Thus, possessing these HLA-alleles is merely 
not sufficient to maintain EC status and suggests that other factors play a part in achieving 
sustained viral control.  
2.3.3 Innate immunity 
The first line of defense against infection, the innate immunity, provide immediate non-
adaptive defense that last for a short period of time. Innate immunity is considered “non-
specific” due to the rapid and short-lasting nature of responses against any pathogen. The 
importance of innate immunity in HIV infection, or any infection for that matter, is recruitment 
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of immune cells via secretion of small molecules called cytokines and chemokines, and 
activation of the long-lasting and specific adaptive immune system through antigen 
presentation. Although HIV infection is a chronic disease and thus it appears more relevant to 
study adaptive immunity, there are unique properties of the innate immune response in ECs 
that have been described in the context of spontaneous control (figure 4).  
Dendritic cells (DCs) are antigen presenting cells, which main function is to process foreign 
antigens and present it to components of the adaptive immune system, making them a key 
player in the linking bridge between innate and adaptive immunity. Plasmacytoid DCs (pDCs), 
a subset of DCs, respond rapidly against viral infections by secreting significant amounts of 
proinflammatory cytokines such as interferon alpha (IFNa), interleukin-12 (IL-12), tumor 
necrosis factor (TNFa) and macrophage inflammatory protein (MIP-1b). The secretion of these 
cytokines promotes inhibition of viral replication and initiate cascades of other innate and 
adaptive immune responses. Although there is a massive depletion of immune cells during 
acute HIV infection, that can be partly restored by ART, pDCs are preserved in ECs and 
maintain a preserved functionality to reduce viral replication (93,94).     
Natural killer (NK) cells, a counterpart to the T cells of adaptive immunity, possess anti-HIV 
properties by producing pro-inflammatory cytokines and cytotoxic molecules. Control of HIV 
replication is associated with expression of HLA class I alleles in combination with expression 
of certain killer cell immunoglobulin-like receptors (KIRs, regulatory receptors expressed on 
surface of NK cells) that serve as ligands to these HLA alleles. Expression of KIR3DS1 
together with its ligand HLA-Bw4-80I activates NK cells and results in lower viral load set 
point and reduced risk of disease progression (95). Similar observation was reported that 
KIR3DS1+ NK cells are preferentially expressed in HLA-Bw4-80I+ subjects during acute HIV 
infection and efficiently inhibit viral replication in target cells expressing the HLA-Bw4-80I 
allele (96). While some HIV controller cohorts observe an enrichment of certain KIRs in their 
cohort, other cohorts have failed to do so (65,97). In addition, the later study (97) also 
demonstrated that antiviral capacity of NK cells is not particularly strong nor present in all ECs, 
indicating that the NK cell-mediated inhibition of viral replication is not a necessity for 
maintenance of viral control.  
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2.3.4 Adaptive immunity 
The adaptive immune system is a highly specialized system that takes place after the innate 
immune system and is acquired to respond to pathogens, eliminating them effectively. The 
adaptive immune system is highly sophisticated to remember and recognize the re-encounter 
of pathogens, providing a long-term protection. In chronic HIV infection, where there is a 
constant turnover of virions in different variabilities, the adaptive immune cells (B and T 
lymphocytes) fails to efficiently clear the infection.  
In ECs, an effective HIV-specific immune response is considered to be important for mediating 
long lasting viral control. Components of the adaptive immune system, neutralizing antibodies 
and HIV-specific CD4+ and CD8+ T cells, are the dominant factors in the suppression of HIV 
replication. However, it is still debated upon if one of these components is the cause of an 
individual developing EC status or if they merely play part in maintaining viral replication. 
Components of cellular and humoral immunity that mediate viral control are presented in the 
figure below.        
 
Fig 4. Immune defense mechanisms that contribute to natural HIV control in ECs. Reprinted with permission 
from (68).  
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2.3.4.1 Humoral immunity and antibodies 
The production of antibodies (Abs) by B lymphocytes constitutes an important part of the 
adaptive immunity and is responsible for the protection against extracellular pathogens. 
Besides the progressive depletion of CD4+ T cells, which is partly reconstituted after ART, 
HIV infection also has an impact on B cells, leading to a dysfunctional and impaired B cell 
state. The ineffective antibody response against HIV is due to several factors, including high 
HIV variability, rapid viral mutation rate, poor Ab access to conserved regions of the surface 
protein Env and functional exhaustion of effector B cells among others (98,99).      
Broadly neutralizing Abs (bNAbs) are Abs able to target and neutralize several HIV strains, 
and differ from conventional Abs that provide specificity against merely one particular viral 
strain or epitope. bNAbs can target the conserved regions of the Env protein despite the highly 
variable nature of HIV. In the context of chronic infection (particularly highly mutating viruses, 
such as HIV and Influenza) and vaccine strategies, bNAbs has been studied extensively (100). 
Several studies have demonstrated that only a small fraction of ECs are able to produce bNAbs 
against HIV despite low-grade viral replication. In a cohort of LTNPs, including ECs and 
viremic controllers, only 7% of the ECs had detectable levels (101-103). Most studies actually 
conclude that neutralizing Abs are rare in ECs and levels are not different to other HIV-infected 
subjects with different disease progression rate. Instead, viral evolution has been associated 
with the development of bNAbs (104), suggesting that levels of bNAbs conjugates with higher 
viral load (62,105,106). Nevertheless, even though the levels of bNAbs is not to a great extent 
associated with spontaneous HIV control, understanding the B cell response in ECs and other 
HIV-infected subjects could provide a blueprint for effective prophylactic vaccine purposes.  
Another B cell associated mechanism of clearing infectious agents is the antibody-dependent 
cell-mediated cytotoxicity (ADCC), a cytolytic mechanism based on Ab-coating an infected 
cell and thereby promote lysis of target cell by effector cells (mainly NK cells). Viral load was 
reduced after rectal vaccinal challenge in macaques and associated with ADCC activity, 
suggesting a protective potential of ADCC in controlling HIV infection (107). In contrast to 
bNAbs, the measurement of specific Abs that execute ADDC was significantly higher in ECs 
than in viremic subjects. Specifically, higher levels of Env- and Vpu-specific Abs were 
observed in ECs than viremics that were capable of activating NK cells and mediating cytolytic 
activity (105,108). However, evaluating ADCC response has also been demonstrated to be a 
bit complicated mainly due to the nature of heterogeneity in ECs. The true role of “protective” 
bNAbs and ADCC Abs in natural HIV control still remains controversial.  
 
 
 
   14 
2.3.4.2 CD4+ T lymphocytes 
CD4+ T lymphocytes, also known as CD4+ T cells or T helper (Th) cells, are a central 
component of the immune system as its main task is to provide “helper” functions to other 
components of the immune system. They are crucial for promoting production of different Abs 
by B cells, and for the activation and proper function of cytolytic CD8+ T cells and 
macrophages. Upon presentation of foreign antigens from an antigen-presenting cell, the Th 
cell secretes different cytokines which promote the cell to develop and mature into several 
different Th lineages (Th17, Th22, Tfh and T regulatory cell among others), depending on the 
nature of the pathogen and which immune function that requires aid. Briefly described, the 
CD4+ Th cells are an important factor for regulation of immune responses through coordination 
of humoral and cellular immunity. 
Central for HIV infection is the progressive loss of CD4+ Th cells as it is the primary target of 
the virus. The size and composition of CD4+ Th cell population decreases both in the 
circulation and body sites such as the gastrointestinal mucosa. The homeostasis is deeply 
disturbed and thus the helper function of CD4+ Th cells is also affected (109). In particular, 
the CD4+ Th cells that recognize HIV-derived peptides (referred to HIV-specific CD4+ T 
cells) is more affected by the infection than other subsets (110). In the context of control, ECs 
have a higher functional avidity of HIV-specific CD4+ T cells than infected subjects with 
higher virus levels in blood. Several studies have demonstrated that HIV-specific CD4+ T cells 
of ECs secrete IL-2 and IL-21 to a greater extent and are more polyfunctional than in viremic 
subjects, which is associated with a better capacity of the cytotoxic activities of CD8+ T cells 
(111,112). A study by Harari et al showed that the frequency of IL-2-producing HIV-specific 
CD4+ T cells was negatively correlated with levels of viremia, both in blood and lymph node. 
In individuals with up to 15 months of successful ART, the IL-2 producing cells were 
significantly lower than in ECs, indicating that HIV-specific CD4+ T cells are not restored 
despite treatment and could represent a marker of protective immunity (113). This study as 
well as others, postulates that the observed higher functionality of CD4+ T cells in ECs are a 
consequence of controlled viral replication rather than the cause of it (114).  
The expression of inhibitory immunoregulatory receptors on HIV-specific CD4+ T cells in ECs 
may also affect the state of natural control. Cytotoxic T lymphocyte antigen 4 (CTLA-4) is 
expressed on activated T cells and can antagonize the signaling mediated by CD28, thus 
inhibiting T cell activation and suppressing proper T cell function. CTLA-4 was upregulated 
on HIV-specific T cells in untreated and treated virally suppressed individuals but not in ECs 
(115). This indicates that the expression of inhibitory immunoregulatory receptors on HIV-
specific CD4+ T cells may suppress a proper proliferation in response to HIV antigen as well 
as properly function.     
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2.3.4.3 CD8+ T lymphocytes 
A strong and effective HIV-specific T cell immune response, in particular HIV-specific CD8+ 
T cells, has been demonstrated to be the dominating factor in mediating long lasting viral 
control. This central component of HIV immune control integrates with and is supported by 
other immune components (DCs, macrophages, ADCC etc.) to achieve this.   
The ability of CD8+ T cell to directly kill infected cells as well as its association with protective 
HLA class I molecules and viral control, makes CD8+ T cell immunity generally “regarded as 
the backbone” in mediating the viral regulative activity in ECs (68,116). Studies focus 
extensively on this type of immune response in order to convert immune protection of HIV to 
vaccine development. Several research groups have shown that ECs are able to maintain a high 
frequency of functional HIV-specific CD8+ T cells that are able to effectively kill HIV-infected 
cells via production of several cytokines and chemokines (117-119). The increased function of 
these CTLs in ECs is demonstrated by their ability to synthesize large amounts of granulocytic 
components such as granzyme B and perforin, enabling greater killing capacity of HIV infected 
cells (63,120). The increased function of CD8+ T cells has been demonstrated to be associated 
with expression of distinct transcription factors, in particular T-box transcription factor T-bet 
(T-bet) (121). The enhanced antiviral activity of CD8+ T cells in ECs also appears to be 
mediated via Gag-restricted epitopes on CD8+ T cells (122). So called CTL escape mutations, 
i.e. HIV epitopes undergoing mutations in order to escape presentation to CTLs and thereby 
prevent killing of infected cell, has been demonstrated to be very specific in ECs and often 
related to protective HLA alleles, which enables CD8+ T cells to control the viral replication 
(77,123-125). Thus, specific mutated HIV-1 epitopes targeted by CD8+ T cells in combination 
with certain HLA alleles can be enhancing the polyfunctional effects of viral control.   
The persistent antigen exposure to effector T cells during chronic HIV infection leads to an 
altered differentiation state, called T cell exhaustion, which manifests as loss of effector 
function and failure to effectively clear the infection (126,127). The sustained up-regulation of 
multiple inhibitory receptors (PD-1, TIGIT, CTLA-4 among others) maintain this 
dysfunctional state of T cells and is associated with inefficient control of chronic infections. 
Extensive studies have shown positive effects of blocking the inhibitory molecules associated 
with T cell exhaustion; CD8+ T cell immune response has been reversed and reinvigorated, 
both during chronic viral infections such as HIV and tumor immunity (128). However, the 
impact of T cell exhaustion on effective CD8+ T cell response (as well as impact on CD4+ T 
cells) among ECs is poorly understood and further understanding how exhaustion is associated 
with maintenance of natural HIV control is highly relevant for future HIV eradication 
strategies. 
During recent years, research has also been focused on evaluating the more controversial non-
cytolytic, suppressive antiviral activity of CD8+ T cells rather than merely the direct killing 
capacity. It has been claimed in HIV controllers that a subset of their CD8+ T cells are able to 
effectively inhibit viral replication in HIV-infected cells ex vivo (129-131). Also, a recent study 
performed in a simian immunodeficiency virus (SIV) animal model, reported that Chinese 
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macaque monkeys, upon administration of an oral therapeutic vaccine comprised of inactivated 
SIV particles and commensal bacteria Lactobacillus plantarum, induced a tolerance against 
towards SIV (132). This tolerance was observed to be mediated by MHC-E-restricted and non-
cytolytic CD8+ T regulatory cells, a concept that is very controversial as there is limited data 
on CD8+ T regulatory cells as well as MHC class E. However, Carnathan and colleagues were 
not able to confirm this tolerance when conducting the same experiment in Indian rhesus 
macaques (133).  
Although other research groups have established a suppressive, immunoregulatory CD8+ T 
cell activity in HIV controllers, there is very limited data on mechanism, transcription factors 
involved and markers associated with this cell subset. There is some data on CD8+ T regulatory 
cells in the field of cancer research where a lineage of CD8+ T cells have been shown to inhibit 
development of autoimmune diseases and regulate anti-tumor immunity (134-136). Although 
this subset, driven by transcription factor Helios for stable phenotype, is until now only 
described in mice models regarding mostly tumor immunity (136,137). Personal 
communication with Dr Hye-Ju Kim revealed a HLA-E-dependent suppressive activity of 
these cells via involvement of KIRs, similar that has very recently been observed in a small 
cohort of ECs (138). Several other studies have implicated that immunoregulatory mechanisms 
might be involved in maintaining low viral replication and preservation of CD4+ T cells. The 
ECs in a study published by Gaardbo et al displayed elevated percentage of activated T 
regulatory cells and preserved IL-10 production, suggesting that immunoregulatory cells is 
playing part in preserving CD4+ T cell levels and the non-progression of HIV infection (139). 
As described earlier, HIV is merely a disease of lymphoid tissues and findings from Fukazawa 
et al have shown that B cell follicles in lymph nodes of rhesus monkey ECs act as sanctuary 
site for persistent SIV replication (32). As a consequence, potent anti-viral CD8+ T cell 
responses possess limited ability to enter these sanctuary sites, allowing HIV to sustain in Tfh 
cells. Buggert et al recently published the first data on lymph node HIV-specific adaptive 
immunity in ECs. Their data demonstrate that ECs have high levels of HIV-specific CD8+ 
tissue resident memory T cells (TRM), a non-circulating cell type residing primarily in 
peripheral tissue, in lymph nodes. The HIV-specific TRM possess enriched effector-related 
immune genes and signatures in comparison to HIV-specific non-TRM. Their data suggests that 
CD8+ T cell immunity against HIV of ECs is mostly mediated by TRM in lymph nodes 
(140,141). Personal communication with Michael R. Betts’ research group also describes 
further interesting findings in lymph nodes of ECs; the majority of CD8+ T cells, including 
HIV-specific ones, in lymph nodes of ECs do not co-express cytolytic molecules perforin and 
granzyme B. In addition, these cells exhibit less killing capacity compared to their blood 
counterparts. Despite the reduced cytolytic capacity, lymph nodes CD8+ T cells from HIV ECs 
are highly polyfunctional, display a distinctive transcriptional profile, and possess strong viral 
suppression ability. These results suggest that alternative mechanisms could be involved in the 
control of viral replication in lymph nodes of HIV ECs. 
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2.3.5 Immune activation, microbial translocation and the gut microbiota 
As described, HIV mainly targets and infects CD4+ T cells but has profound effects on the 
immune system as a whole. The constant viral replication results in a chronic activation of the 
immune system which is highly correlated to persistent immunological dysfunction. This 
systemic immune activation is initiated early during the primary infection and is closely related 
to disease progression and development of AIDS (142). The characteristic high T cell turnover, 
B and T cell activation and increased levels of pro-inflammatory cytokines is observed even in 
patients with suppressed viral replication due to successful ART (143). ART has indeed 
provided a tremendous success in reducing mortality in HIV-infected individuals but the 
infected subjects rarely achieve same levels of immune activation as age- and sex matched non-
infected healthy controls. They are also at a higher risk for non-AIDS related complications 
(e.g. cardiovascular diseases, metabolic syndromes, non-AIDS cancer, etc.) than non-infected 
(144-146). The co-expression of surface markers CD38 and HLA-DR on CD4+ and CD8+ T 
cells was described early on as a predictor for immune activation and disease progression in 
HIV infection, and is still today the most prominent used markers of immune activation 
(142,147,148). In addition, soluble markers such as kynurenine/tryptophan ratio of the 
indoleamine 2,3-dioxygenase-1 (IDO) pathway and CD14, CD163 and IL-6 are used as a 
correlate of activated monocytes among other cell types (149). One might postulate that ECs, 
having suppressed levels of plasma viremia, would therefore also have levels of immune 
activation similar to healthy non-infected subjects. In contrast, several studies have showed 
that ECs actually have significantly higher levels of activated T cells than both healthy non-
infected and ART-suppressed subjects, as well as a higher portion of activated monocytes 
(150,151). Pereyra et al demonstrated an increased prevalence of atherosclerosis and 
monocyte activation marker, soluble CD163, in ECs with no previous record of 
cardiovascular disease, in comparison with healthy and chronically HIV-infected subjects 
(152). The abnormally high immune activation seen in natural control of ECs provides a 
profound risk of non-AIDS complications in ECs.  
The role of immune activation as a central feature of HIV immune pathogenesis is very 
complex and multifaceted. One important contributing factor is the presence of gut microbial 
products in blood. Microbial translocation occurs very early during HIV infection as the gut 
associated lymphatic tissue (GALT) in gut lumen is damaged due to loss of tight junctions, 
allowing microbial products from gastrointestinal (GI) tract to enter peripheral tissue and blood 
circulation (figure 5). GALT harbors a majority of subsets of CD4+ T cell (pro-inflammatory 
IL-17 and IL-22 producing cells) that are crucial for gut homeostasis and protection of the body 
from gut microbial products. CD4+ T cells are substantially deleted in the GALT throughout 
all stages of HIV infection and the skewing of IL-17/IL-22 producing CD4+ T cells is a major 
contributor of immune activation (153-155). In addition, the gut bacterial products (comprised 
of peptidoglycan, lipoteichoic acid, lipopolysaccharide (LPS) of the outer wall of gram-
negative bacteria, flagellin and ribosomal DNA among others) that leak into the circulatory 
system causes an activation of the immune components (156-159). Microbial translocation is 
not solely limited to HIV infection but has also been described in conditions such as 
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inflammatory bowel disease (IBD), celiac disease and hepatitis C infection (160-164). 
Microbial translocation is very often associated with a dysbiosis of the composition of the gut 
microbiota. Considering that our gastrointestinal tract inhabits approx. 1014 normal flora of 
microorganisms living in symbiosis (165), a breach of the protective gut lumen during HIV 
infection as well as shift or dysbiosis in the composition of normal gut flora could have a huge 
impact on disease progression and HIV persistence. Several treatment strategies, aiming to 
decrease damage to the epithelium, enhancing mucosal immunity and restoring gut microbiome 
in order to reduce systemic immune activation, have been postulated.      
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5. The intestinal epithelium and infiltration of commensal bacteria during HIV. Reprinted with permission 
from (166).  
Most studies relate HIV infection to a decreased bacterial richness and diversity in the gut, and 
an attributed immune activation driven by microbial translocation(167,168). A seminal paper 
by Brenchley et al showed that ECs had significant higher levels of markers of microbial 
translocation than non-infected and yet maintained lower levels than progressors (169). In a 
small cohort of ECs, IL-17 producing T cells was intact in gut biopsies and displayed only a 
trend towards monocyte activation (170). A very interesting study by Kim et al investigated 
the impact of ART on gut immunology in ECs (171). Four ECs were given standardize ART 
regime for 9 months. Before ART, the number of several CD4+ T cell subsets were similar 
between ECs, non-infected and long-term ART treated subjects. However, the frequency of 
Th17 cells was increased compared to non-infected. In addition, ECs displayed higher levels 
of IL-6 and D-dimer than non-infected, something that ART was not able to reverse.      
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There are very limited data on the gut microbiota composition in ECs, mostly due to the limited 
number of ECs and perhaps somewhat difficulty in investigating the gut microbiome as one 
requires stool sample for the determination. Three papers have described the bacterial 
composition in spontaneous control of HIV. The first paper, published by Vujkovic-Cvijin et 
al included only one LTNP so drawing a proper observation and conclusion is difficult (172). 
The second paper was published from our research group at Karolinska Institutet and included 
three ECs. It showed that there was a lower interindividual variation in bacterial composition 
among these three. The ECs differed from viremic subjects regarding bacterial phylum and had 
a similar composition as non-infected healthy subjects (173). Somewhat controversial data was 
published by Noguera-Julian et al, where 8 ECs were included in the study, investigating the 
effect of HIV-infection on the gut microbiome. They found that HIV risk factors, rather than 
HIV status (including EC status), such as sexual orientation are strongly associated with fecal 
microbiota composition (174). The most extensive study of the gut microbiome in ECs is 
probably paper I included in this thesis (175) but the scoop of that paper will be discussed 
later in accordance. The varied observed data among ECs regarding immune activation, 
microbial translocation and gut dysbiosis indeed reflects the heterogeneity of this patient 
population. It further emphases the need for more accurate studies on the role of host-
microbiota interaction for this unique patient group.     
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3 AIMS 
The main objective of this thesis was to investigate a variety of different of immune and 
microbiome parameters associated with spontaneous control of HIV-1 infection in Elite 
Controllers.  
The specific aims were: 
Paper I: To investigate if HIV infection affects the gut microbiota in Elite Controllers and 
patients with progressive HIV infection. Also, to explore the association between composition 
and functionality of the gut microbiome and systemic inflammation.  
Paper II: To determine the antibody profile against HIV-1 proteomes in Elite Controllers, 
using a modified version of the novel antibody assay “LIPS”.  
Paper III: To understand the underlying immune mechanisms by which disease progression 
is prevented in Elite Controllers, by adapting a comprehensive analysis of host transcriptomics- 
and proteomics data, and clinical phenotypes.  
Paper IV: To investigate the expression pattern of inhibitory receptors, associated with T cell 
exhaustion and defect T cell function, on different CD4+ T cell memory populations in Elite 
Controllers. 
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4 MATERIAL AND METHODS 
4.1 STUDY DESIGN AND SAMPLE COLLECTION 
The premises for all the studies included in this thesis are the study subjects in the Swedish 
Elite Controller cohort. The inclusion criteria for being defined as an EC varies greatly across 
different cohorts and has created a huge discrepancy among observed data. Therefore, we based 
our inclusion criteria on recommendations from CASCADE (The Concerted Action on 
SeroConversion on AIDS and Death in Europe collaboration, part of the EuroCoord European 
network that collects HIV cohort collaboration), in order to maintain a level of standardization. 
The Swedish national InfCare database, which includes 100% of the Swedish patients, was 
used to evaluate all Swedish HIV infected individuals. At the time, out of 22 identified in 
Sweden as EC, 19 subjects approved to participate in the studies and met either of the two 
following criteria;  
1. HIV-1 positive status for ≥1 year with HIV-1 RNA levels below 75 copies/ml on ≥3 
consecutive determinations, spanning over at least 12-month ART-free period with all 
previous determinations below 1,000 copies/ml (n = 15) or 
2. HIV-1 positive status for ≥10 years with ≥2 consecutive HIV-1 RNA level determinations 
with ≥90% of all HIV-1 RNA determinations below 400 copies/ ml (n = 4) 
Four female ECs had been subjected to ART for a very short time due to pregnancy. They were 
all on treatment for 3.5 months expect for one EC that was on treatment for 14 days. However, 
the treatment was not within the time-range of the inclusion criteria #1 of what all four EC were 
subjected to. In addition, n=23 non-infected subjects (age- and sex matched healthy controls), 
n=19 HIV-1 infected patients on long-term ART (mean 17y on ART) and treatment-naïve, 
viremic patients (n=38) were recruited. See respective papers for more details about study 
subjects’ demographic and clinical characteristics.   
Whole blood was collected from the participants. EDTA-treated blood was further processed 
with Hypaque-Ficoll density gradient (GE Healthcare) to isolate peripheral blood mononuclear 
cells (PBMCs). Upon counting, the cells were cryopreserved at-150 oC in fetal bovine serum 
containing 10% DMSO (Sigma-Aldrich) at a concentration of 107 cells/ml. Serum and plasma 
were also collected and stored at -80 oC. In addition, a fecal sample was collected (Paper I) in 
a sterile tube when participant was able to donate sample in connection to their visit at the out-
patient clinic and immediately stored at -80 oC. Participants who were not able to contribute 
on-site instead provided a fecal sample at a later moment at their homes, using the PSPÒ Spin 
Stool DNA sampling tube (Stratec Biomedical). The tube was either delivered to the clinic by 
the participant or sent by mail, and immediately stored at -80 oC. 16 ECs and 16 healthy subjects 
were able to donate a fecal sample. In Paper I, treatment-naïve patients from the T-study cohort 
were included instead of viremic patients from the Swedish Elite Controller cohort, mainly due 
to the availability of fecal samples (n=32). 
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4.2 METHODOLOGIES 
Several different experimental procedures have been used in this thesis in order to approach 
the many immunological and microbiological aspects of understanding control in HIV ECs. 
The methods are described in more detail in the respective papers, but below follows a brief 
summary on the relevant methods and related application in each paper. 
4.2.1 Markers of immune activation, microbial translocation and tryptophan 
catabolism (Paper I) 
In Paper I, soluble markers of immune activation and microbial translocation was determined 
in plasma using ELISA; LBP (Hycult Biotech, Netherlands), sCD14 and IL-6 (R&D, 
Minnesota, USA) and hs-CRP (Abcam, UK). Metabolites of tryptophan catabolism were 
analyzed in plasma using high-performance liquid chromatography (HPLC) by Bevital, 
Norway.  
4.2.2 Sequencing of gut microbiota and sequence analysis (Paper I) 
In order to identify microbial organisms in the gut, we made use of the 16S ribosomal RNA 
sequencing, a technique based on PCR-amplicons targeting the V3 and V4 region of bacterial 
16S rRNA gene. It is a commonly used method for study bacterial phylogeny and taxonomy 
due to the highly preserved 16S rRNA bacterial gene being present in almost all bacteria. First, 
DNA was extracted from fecal samples using the PowerSoil DNA Extraction Kit (MO BIO 
Laboratories, Carlsbad CA, USA) according to the manufacturer’s instructions and then 
sequenced on IlluminaTM platform. Second, obtained data was processed using the Mothur, a 
bioinformatic tool for analyzing 16S rRNA gene sequenses. The bacterial richness estimators 
(ACE and Chao1) and diversity indices (Shannon and Simpson) were calculated using R/vegan 
library. In addition, the microbiome function was analyzed with PICRUSt (Phylogenetic 
Investigation of Communities by Reconstruction of Unobserved States), a bioinformatic tool 
that provides insight into the metagenomic functional gene content of the microbiome, based 
on 16S rRNA data and the KEGG database. 
Figure 6. Schematic illustration of a 16S rRNA sequencing and data processing. Heatmap adapted from paper III.  
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4.2.3 Luciferase immunoprecipitation systems (LIPS) (Paper II) 
In Paper II, we made use of a modified antibody quantification assay, “luciferase immuno-
precipitation systems (LIPS)”, to perform antibody profiling against several HIV-1 proteins in 
ECs. LIPS is a fluid-phase immunoassay with high specificity and sensitivity for 
conformational epitopes. Briefly, a Renilla luciferase antigen fusion construct against six HIV 
proteins (p24, reverse transcriptase, integrase, protease, Tat and gp41) was transfected in 
HEK239 cells to generate a lysate. After mixing the lysate with the subject’s plasma and 
additional reagents, luciferase activity was determined by measuring light-forming units (LU) 
with Infinite® 200 PRO, Tecan. The antibody response profile was further organized using 
principal component analysis (PCA) and hierarchical clustering. PCA is a statistical dimension-
reduction method that allows reduction of a large set of data to a small set, while still 
maintaining most of the information. In addition, hierarchical clustering was accompanying 
PCA to explore hidden patterns in larger data sets and is suitable for large clinical datasets such 
as described in paper II and III.   
4.2.4 RNA sequencing and data processing (Paper III) 
In order to identify genes and factors that could play part in HIV control, a comprehensive 
strategy was addressed involving analysis of host transcriptome, proteomic data and clinical 
phenotype. The host transcriptome of the study subjects was determined with RNA sequencing, 
a method widely used to analyze the presence and quantity of the constantly changing RNA 
molecules in human cells. Briefly described, RNA was isolated from PBMCs or plasma 
samples using the RNeasy Mini kit (Qiagen, Hilden, Germany) and further quality checked 
with an Agilent 2100 Bioanalyzer (Agilent Technologies, Germany). The library preparation, 
e.g. preparation of RNA to make it compatible with the sequencing system, was carried out 
with poly(A) enrichment in order to isolate messenger RNA fragments (mRNA) and remove 
ribosomal RNA. The sample was sequenced on HiSeq2500 system (Illumina platform). Data 
processing, or assembling the transcriptome data, involved several steps and the usage of 
several bioinformatic tools, figure 7. DE analysis (using Limma R package) and variant calling 
(GATK software) together with HLA-typing was used to identify differential expressed genes, 
hence identifying genes that is transcribed to a higher or lower frequency in our samples. The 
obtained data was further analyzed by gene ontology annotation tool (STRING, UniProt) to 
identify interactions among the identify differential expressed genes.   
 
Figure 7. Schematic protocol of RNA sequencing. Adapted from Paper III. 
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4.2.5 Targeted proteomics (Paper III) 
With the obtained data described in section 3.2.4, we performed protein analysis (targeted 
proteomics) using the proximity extension assay (PEA) (Olink Bioscience, Sweden), an 
immunoassay for protein quantification and simultaneous detection of several proteins in one 
sample. Based on the gene ontology annotation of the transcriptome, 92 soluble factors that is 
part of the Olink Immuno-oncology panel were chosen for further assessment in plasma 
samples of the study subjects. The panel constituted of proteins involved in cell-surface 
receptor signaling, programmed cell death and cytokine mediated signaling pathways. The 
principle of PEA is the binding of an antibody, linked to a proximity probe or oligonucleotide, 
to your protein of interest. Upon binding, the proximity probes come in close contact and 
hybridize to each other. By adding a DNA polymerase, an extension of the now hybridizes 
oligonucleotide and DNA amplicon is created that is quantified by real-time PCR. Proteins of 
interest was further validated with conventional ELISA (R&D, Minnesota, USA). Data 
analysis of the proteomics involved generation of protein profile (heatmap) using Qlucore 
Omics Explorer v3.2.  
 
Figure 8. Schematic protocol of Targeted Proteomics. Adapted from paper III. 
4.2.6 Flow cytometry (Papers I and IV) 
For determination of immune phenotype on lymphocytes, multi-parametric flow cytometry 
analysis was used. Flow cytometry is a widely used method for simultaneous detection of a 
single-cell’s physical characteristic such as size, granularity and other markers of interest. The 
working principle of the method is detection of cells labelled with a fluorescent antibody that 
stream through lasers while flowing in fluid. Flow cytometry allows for detection of several 
cellular components at single-cell level and can be used for identification of a specific cell 
population from a complex sample.   
As described in Paper I and IV, study subjects PBMCs were labeled with fluorescent-
conjugated monoclonal antibody against cell markers of interest. Upon fixation and 
permeabilization, cells were acquired on a 4-laser LSR Fortessa (BD Bioscience) and further 
analyzed with FlowJo software (Treestar) for gating strategy. In Paper IV, Simplified 
Presentation of Incredibly Complex Evaluations (SPICE, developed at NIH, USA) was applied 
on the flow cytometry data. SPICE is a sophisticated visualization software that allows 
organization of complex flow cytometry data into clear presentation and evaluation. When 
investigating several aspects of a large data set, as the co-expression pattern of several receptors 
on one cell type described in Paper IV, SPICE provides both a simple presentation of the data, 
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as the name implicates, and appropriate statistical testing of the data set (permutation and t-
test).   
 
 
 
 
 
 
 
 
Figure 9. Illustration of a SPICE diagram. Adapted from Paper IV. 
4.3 BIOINFORMATIC AND STATISTICAL ANALYSIS 
The relevant bioinformatic tools have been described briefly above together with the associated 
method. Below is a description of the statistics used in respective paper.  
Paper I 
When comparing inflammation variables, subject demographics, bacterial diversity, richness 
and composition between two groups, the Mann-Whitney U-test was used while Kruskal-
Wallis was applied for multiple group comparison. Spearman’s rank test was used for 
correlation analyses between bacterial genera and composition, functional pathways and 
markers of inflammation & immune activation. Bacterial genus and function were grouped in 
heatmap according to Ward hierarchal clustering. Any associations with a Benjamini-
Hochberg adjusted p-value cutoff below 0.01 was considered relevant and parameters 
associated with less than two bacterial species was discarded when plotting heatmap. Lasso 
regression analysis was used to evaluate the power of classification of bacterial composition 
between different study groups.  
 
Paper II 
For comparison of antibody levels between the different study subject groups, non-parametric 
Mann-Whitney U-test was used with p-value <0.05 considered significant. PCA and analysis 
of heatmap (antibody profile) was performed using Qlucore Omics Explorer version 3.2. The 
PCA was performed with a false discovery rate (FDR) adjusted p (q) <0.05 and the more 
stringent <0.001 using ANOVA. The statistical analysis was performed with GraphPad Prism 
software (San Diego CA, USA).    
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Paper III 
When comparing demographic and clinical characteristic data in our study population as well 
as difference in protein levels, descriptive statistics was used; Mann-Whitney U-test when 
comparing two groups and Kruskal-Wallis for multiple group comparison (p-value <0.05 
considered significant). Hierarchical clustering analysis was performed with a FDR adjusted p 
(q) <0.001 using ANOVA. The FDR adjusted p (q) <0.05 and the more stringent <0.001 using 
ANOVA was used as cutoff.  
 
Paper IV 
Variables between two study groups were analyzed using Wilcoxon matched-pair rank test 
whereas two-way ANOVA with Bonferroni correction was applied when analyzing three or 
more groups. Spearman’s rank test was used for correlation analyses. The statistical analysis 
was performed with GraphPad Prism 6.0. The SPICE software allows for permutation tests 
when analyzing diversity between the study groups.   
4.4 ETHICAL CONSIDERATIONS 
All study participants were given both written and oral information about the studies. All 
participants provided written informed consent in accordance with the Declaration of Helsinki. 
The Regional Ethical Council in Stockholm, Sweden approved all studies; 2009/1485-31, 
2013/1944-31/4 and 2014/920-32. No harm or discomfort was brought to the study subjects 
more than the circumstances of providing a fecal- and blood sample.   
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5 RESULTS AND DISCUSSION 
Since the discovery that a limited fraction of HIV-infected individuals are able to 
spontaneously control the infection for long period of time without treatment, extensive studies 
have been made trying to understand how ECs maintain their control status. Although much 
attention has been focused on the CD8+ T cell response in the setting of elite control, it is clear 
that not all ECs bear protective HLA-alleles. As such, it seems as natural HIV control is 
multifaceted and a comprehensive understanding of underlying factors of elite control is 
therefore required for future advances in this field. In this thesis, I have focused on investigating 
several aspects of immunological and microbiological parameters that is related to and could 
potentially describe the EC-status, including chronic inflammation and gut microbiota 
dysbiosis, humoral (antibody) profile, T cells dysfunction and gene- and protein expression on 
a larger scale. It is my hope that the findings presented here can contribute to further 
understanding of natural HIV control and hopefully contribute to future HIV vaccine and 
eradication efforts.    
PAPER I- RICHER GUT MICROBIOTA WITH DISTINCT METABOLIC PROFILE 
IN HIV INFECTED ELITE CONTROLLERS 
Study background 
Progressive HIV infection is hallmarked by depletion of CD4+ T cells in GALT, microbial 
translocation (leakage of bacterial products to the periphery), gut microbiota dysbiosis and a 
persistent immune activation. Several studies have related HIV infection to a decreased 
bacterial richness and diversity in the gut. However, there are very limited studies on the gut 
microbial composition in spontaneously controlled HIV infection and they are not fully 
extensive. Thus, in this study we aimed to investigate the gut microbiota composition in ECs, 
as well as explore the potential relationship between gut bacterial composition and functionality 
and systemic inflammation.  
Results and discussion 
We found that ECs and non-infected (“healthy”) subjects had similar bacterial richness and 
diversity in their fecal microbiota (assessed by Chao1 and ACE, and Shannon and Simpson 
index, respectively) (figure 10). ECs had a lower degree of inter-individual variation of 
bacterial composition while untreated HIV-infected subjects had a larger spread. We observed 
a compositional difference in bacteria genera and found that ECs had a unique bacterial 
signature at genus level. Entirely 17 genera were significantly different from ECs and other 
study groups (untreated HIV- infected and healthy subjects). Genera such as Succinivibrio, 
Sutterella and Oscillospira were enriched in ECs while Blautia and Anaerostipes genera were 
found to be depleted. Several of these 17 significantly different genera had correlation to 
markers of immune activation (CD38, HLA-DR). For example, Sutterella, a commensal 
bacteria in the GI tract, was inversely correlated to activated CD4+ and CD8+ T cells. The 
metagenomic functional content of the gut microbiota, which is predicted with the PICRUSt 
analysis tool, revealed that several metabolic pathways were significantly different between 
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ECs and the other study groups. For example, the predicted pathway related to carbohydrate 
metabolism in the gut bacteria was significantly reduced in ECs compared to both untreated 
HIV- infected and healthy subjects (p<0.001 and p<0.01, respectively). The peroxisome 
proliferator-activated receptors (PPAR)- signaling pathway that play an important role in 
cellular differentiation and metabolism of carbohydrates, lipids and proteins, was significantly 
reduced in untreated patients compared to ECs (p<0.01). Altogether, this very unique bacterial 
signature and metabolic profile observed in ECs strongly suggests that bacteria genera is 
associated with natural HIV control.  
 
 
 
 
 
 
 
 
 
 
Figure 10. The bacterial richness (assessed by Chao1 and ACE) and diversity (Shannon and Simpson index), in 
ECs, treatment-naïve HIV-infected and healthy subjects.  
 
PAPER II- QUANTITATIVE HUMORAL PROFILING OF THE HIV-1 PROTEOME 
IN ELITE CONTROLLERS AND PATIENTS WITH VERY LONG-TERM 
EFFICIENT ANTIRETROVIRAL THERAPY 
Study background 
Proper assays for measurement of latent reservoirs is essential for elucidating HIV eradication 
strategies. Latent infection results in prolonger Ab response and thus measurements of anti-
HIV Ab levels, in particular the conformational HIV epitopes, can distinguish HIV-infected 
individuals harboring different viral reservoirs sizes (40,176). In this project we aimed to 
investigate the anti-HIV response in ECs by determination of Ab levels, using a modified 
antibody quantification assay termed “luciferase immuno-precipitation systems” (LIPS).    
Results and discussion  
We found that the LIPS assay displayed a strong detection of Ab against six HIV antigens (p24, 
RT, protease, integrase, Tat and gp41). ECs showed significant higher levels of all HIV antigen, 
except for integrase and Tat, compared to long-term ART suppressed subjects (p<0.05) and no 
statistical difference compared to viremic subjects (figure 11). Analysis of the total Ab response 
against all six antigens showed similar; ECs has higher median levels (p=0.001) than ART-
   31 
treated subjects and no difference to viremic subjects. PCA and hierarchal clustering analysis, 
based on the six HIV antigens, revealed that 68% (13/19 subjects) of ART-treated and 26% 
(5/19) of ECs clustered together, while most of the ECs (74%, 14/19 subjects) clustered with 
viremic subjects. Here, we demonstrated that ECs display Ab levels against HIV antigens very 
similar to viremic subjects and that long-term successful ART is associated with lower levels. 
We also showed that ECs cluster with subjects with high viremia in regards of total Ab 
response, indicating that ECs much likely have a constant low-grade viremia that continuously 
fuel the viral reservoirs and maintain an Ab response. The significant lower Ab levels (against 
4 of total 6 HIV antigens) in ART-subjects, compared to ECs, indicate a smaller pool of viral 
reservoir in those subjects. Indeed, those individuals have been subjected to successful 
treatment for several years (median 17y, range 13-20) which could explain an effective 
suppression of viral replication, to a greater extent than ECs may possess by natural means. As 
ECs maintained lower levels of Ab against Tat and integrase compared to viremics, this might 
be associated to a lower frequency of integrated HIV DNA in ECs and thus a lower activity of 
the integrase enzyme (177). The observed heterogeneity in Ab levels among ECs further 
suggests that this small patient population is indeed very heterogenous, despite our stringent 
EC inclusion criteria. Determining merely the antibody profile is not sufficient to elucidating 
factors of viral control and further studies are required.  
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Antibody response against six HIV antigens, in ECs and other HIV- infected individuals.  
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PAPER III- TRANSCRIPTOMICS AND TARGETED PROTEOMICS ANALYSIS 
TO GAIN INSIGHTS INTO THE IMMUNE-CONTROL MECHANISMS OF HIV-1 
INFECTED ELITE CONTROLLERS 
Study background 
Following the work in Paper II, we understood the need for a more broad-range analysis in 
order to investigate factors of HIV control in ECs. Previous studies have mostly focused on a 
specific, predefined immunological pathway or molecule that could explain the halt of disease 
progression in ECs. Therefore, we adapted a comprehensive analysis of host transcriptomics, 
proteomics and clinical phenotypes in ECs, aiming to investigate a systemic, immunological 
program (rather than a single subset) associated with HIV control.    
Results and discussion 
HLA typing revealed that 63% of the ECs (12/19) possessed one or more of protective alleles 
(A*25:01, A*74:01, B*14:02, B*27:05, among others). Some ECs also had HLA alleles related 
to disease progression (B*35:03, B*53:01 among others). Using Differential Expression (DE) 
analysis without gender differentiation, 8 protein-coding genes was differentially expressed 
between ECs and healthy subjects in contrast to 270 protein-coding genes that were 
differentially expressed between ECs and viremics. DE analysis also revealed downregulation 
of CXCR6 and SIGLEC, associated with viral entry and formation, in ECs. In addition, with 
gender-specific DE analysis, we observed 98 transcripts that were differentially expressed 
between male and female ECs (24 upregulated and 74 down-regulated; 51 transcripts were 
protein-coding). Among these, osteoclast differentiation, TNF signaling and Toll-like receptor 
signaling pathway were significantly enriched. No difference was observed between female 
ECs and female healthy subjects, while 86 transcripts were different between male ECs and 
healthy males. When investigating protein-coding gene differences in ECs and viremic 
subjects, we found differences in protein levels involved in cell surface receptor signaling, 
programmed cell death, cytokine response and cytokine-mediated signaling. In particular 
CCL4, CCL7 (ligands to CCR5) and members of TNF family was significant different between 
ECs and viremics (figure 12). In this study, we found that the unique difference in gene 
expression and transcriptomic profile between ECs and viremic subjects were related to 
molecular pathways regulating apoptosis, inflammation and cellular differentiation. The 
elevated level of CCL4, a HIV-suppressive factor produced by CD8+ T cells as well as ligand 
for CCR5 and thus competitor for the viral binding site, together with the downregulated 
CXCR6 and SIGLEC genes in ECs, could partly explain the decreased viral susceptibility of T 
cells in those subjects. Ligands of death receptors (FasL and TRAIL) were lower in EC 
compared to viremics, implicating a lower susceptibility of Fas-induced cell death (178). The 
observed gender difference among ECs, that was not related to sex-linked genes, indicate that 
upon HIV infection, a sex-specific gene process might occur that have an impact in driving 
immunological mechanisms of viral control. Taken together, these difference between ECs 
and untreated patients in several molecular pathways suggests they play a synergistic role in 
HIV control, rather than just one factor making up this control. However, further studies 
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focusing on functionality in individual molecular pathways, while considering a gender effect, 
might be beneficial.     
        
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Protein levels involved in cell surface receptor signaling, programmed cell death, cytokine response 
and cytokine-mediated signaling.  
PAPER IV- HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 ELITE 
CONTROLLERS MAINTAIN LOW CO-EXPRESSION OF INHIBITORY 
RECEPTORS ON CD4+ T CELLS 
Study background 
The T cell response play an essential role in controlling HIV infection. However, the persistent 
HIV-antigen exposure to virus-specific T cells skews them into a dysfunctional state where T 
cells becomes exhausted (133). CD8+ T cell exhaustion in the context of HIV control has been 
studies extensively, however, much less is known about exhaustion in CD4+ T cells, the main 
target cell of HIV. In this study, we aimed to investigate the expression pattern of inhibitory 
receptors, associated with T cell exhaustion and defective T cell function, on different CD4+ T 
cell memory populations in ECs. 
Results and discussion 
Expression of inhibitory molecules associated with T cell exhaustion (PD-1, CTLA-4 and 
TIGIT) on CD4+ T cells was lower in ECs compare to viremic and long-term treated subjects. 
CD4+ T cells co-expressing all three inhibitory markers were significantly lower in ECs 
compared with both long-term treated (p=0.03) and viremic (p=0.002). The inhibitory receptor 
expression pattern revealed a significant difference between ECs and viremic and long-term 
treated but showed no difference to healthy subjects (figure 9). When further dissecting the 
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CD4+ T cell population, the expression level of PD-1, CTLA-4 and TIGIT showed a similar 
trend across all subsets with transitional- and effector memory cells displaying the highest 
expression. There was a correlation between co-expression and T cell activation and clinical 
parameters; CD38+HLA-DR+ (r= 0.8, p<0.001), CD4 count (r= −0.48, p<0.001), viral load 
(r=0.37, p=0.012) and CD4/CD8 ratio (r=−0.37, p=0.001), demonstrating that the frequency of 
expression is highly associated with immune activation and markers of disease progression. As 
discussed earlier, some studies have shown that ECs have increased level of immune activation 
associated with progressive disease and thus one would speculate that the expression levels of 
T cell exhaustion markers would also be higher in ECs (151,179). Although our data 
demonstrate a strong association between immune activation and levels of inhibitory markers, 
only a small fraction of the cells that expressed these markers were activated, implicating that 
exhausted cells are not activated in ECs. Also, we had previously shown that the CD4/CD8 
ratio is a suitable predictor of T cell dysfunction (180,181), which was confirmed in this study. 
Interestingly, we observed that cells co-expressing PD-1, CTLA-4 and TIGIT was positive 
associated with CD4+FoxP3+CD25+ cells (markers of conventional regulatory T cells) (r = 
0.58, p<0.001). Despite the strong correlation, only a small fraction of the exhausted cell 
expressed FoxP3, indicating the presence of another subpopulation of CD4+ T cells that 
express high levels of inhibitory receptors. In this study, we demonstrated that in natural HIV 
control, ECs maintained low levels of inhibitory receptors associated with T-cell exhaustion 
and that ECs are able to maintain low expression levels of marker associated T-cell exhaustion, 
despite several years of ongoing viral infection. Their ability to sustain a “healthy state” of 
distinct CD4+ T cell subsets suggest a potential role of these cells in maintaining the control 
status and further implicates that CD4+ T cell exhaustion is an important component of 
effective HIV control.       
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6 CONCLUSION AND FUTURE PERSPECTIVE 
The existence of ECs provides evidence that long-lasting control of HIV replication is 
achievable without ART. ECs are a central natural model for functional cure and has been 
subject for research for many years, in hope that findings could direct research into novel 
therapeutics and vaccine strategies. However, understanding durable control has been proven 
to be more difficult than anticipated. The heterogeneity among these individuals and the 
multifaceted immunological aspects of control demonstrate that a more comprehensive 
analysis approach is required. This thesis has defined several immunological and 
microbiological parameters associated with spontaneous HIV control by focusing on a broad 
analysis strategy. Here, humoral (antibody) profile, chronic inflammation and gut microbiota 
dysbiosis, T cell exhaustion, and gene- and protein expression have been investigated in ECs 
in order to further define the multifactorial aspects related to durable HIV control.  
The main conclusion from each paper included in this thesis are: 
- ECs have a very different gut microbiota composition than individuals with progressive 
infection and resembles those that are not HIV infected. Their very unique bacterial 
signature, metabolic profile and rich bacterial gut microbiota suggests they are 
important contributors in the facilitation of natural HIV control (Paper I).  
 
- The antibody profile of the HIV proteomes (p24, protease, RT, integrase, Tat and gp41) 
in ECs suggest an ongoing low-grade viral replication, probably related to the size of 
the HIV reservoirs. The observed difference in antibody levels among ECs demonstrate 
a heterogeneity in this group (Paper II).  
 
- Gene expression analysis and proteomics profiling of ECs suggest a synergetic 
interplay of cell surface receptor signaling pathway, programmed cell death, response 
to cytokine and cytokine-mediated signaling in the mediation of spontaneous HIV 
control (Paper III). 
 
- ECs maintain low expression of inhibitory receptors (CTLA-4, PD-1, TIGIT) 
associated with T cell exhaustion, on their CD4+ T cells. Despite prolonged ongoing 
viral infection, ECs harbor a “healthy state” of CD4+ T cells that might play part in the 
maintenance of their control status (Paper IV).  
Altogether, these conclusions describe the complexity of ECs status and identify factors 
associated with control that is of importance for further studies. We understand that merely 
focusing on one single, defined parameter is not sufficient enough and that there is probably an 
interplay between T cell immunity, Abs, bacteria in the gut and gene- and protein expression. 
Of course, from these studies, we are not able to conclude what is the hen and what is the egg, 
i.e. if one of the above-mentioned factors is the dominating one and the other a consequence of 
that factor, or if there is another unidentified factor that makes up this control. Nevertheless, 
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we have observed several different immunological aspects in ECs and can conclude that several 
factors affect each other in mediating durable HIV control.   
There are some limitations with the studies presented in this thesis. The most noteworthy to 
mention is the limited number of included subjects that hold the EC status. As discussed earlier, 
the prevalence of EC among the HIV-infected population is indeed significant low (less than 
1%) and the huge discrepancy of the EC-definition definitely narrows that number. In our 
cohort, we have adapted a strict definition of ECs and thus limiting the number of subjects that 
meet this criterion. That said, one vital strength of our cohort, that has enabled us to identify 
and correctly include subjects, is the usage of the InfCare HIV national database. In Sweden, 
every HIV-infected subject is enrolled in this database and makes regular visits to the infection 
clinic where determinations of several parameters, including VL and CD4 count, is 
standardized. This information has enables us to follow a potential EC for several years in order 
to determine if he/she truly meets the EC criteria. Thus, the number of ECs in our cohort might 
be low but they are very well-defined.   
I have previously discussed the importance of CD8+ T cell in maintaining the viral control in 
ECs and although the studies included in this thesis do not address the research question, it is 
noteworthy to mention that we aimed to define alternative, non-classical, effector functions of 
CD8+ T cells mediating HIV control. Despite extensive work, we were unsuccessful to provide 
any such data. During my PhD studies, I have received the question “why not put these ECs on 
treatment, for a preventative measure?”. Although it is not the scope of this thesis, I consider 
this question important to address. Several factors speak for ECs being a suitable model for 
functional cure, while some studies suggest the opposite and explain “negative effects” with 
the EC status (182). ECs are able to control plasma viremia to almost undetectable levels but 
HIV RNA and integrated HIV DNA have been detected in peripheral blood mononuclear cells 
as well as occasional viral “blips” with detectable viral levels (183). These data suggest that 
there is a constant, low-grade viral replication for several years that can have a huge impact on 
fueling a constant immune activation in ECs. Also, detectable levels have been shown in rectal 
cells (184), demonstrating that even though ECs maintain low levels of viral replication, the 
levels are indeed detectable and the virus is replication competent. The observed negative 
effects of EC status have developed into suggestions to put these individuals on ART. Some 
studies have demonstrated beneficial effects of ECs receiving ART (185-187); reduced HIV 
RNA levels than the initial low levels, reduced levels of immune activation and dysfunction in 
both blood and gut. However, long-term follow up of the treated ECs in the study by Hatano 
et al demonstrate that the benefits of ART in ECs are considerable low and does not outweigh 
the negative effects such as adverse side effects of drug, psychological effects, etc. (Dr Marcus 
Buggert, personal communication with Dr Steven Deeks). By citing Cokerham et al that “ECs 
and post-treatment-controllers provide additional evidence that functional cure is 
possible…they give us clues about potential novel interventions that might achieve long-term 
control of HIV viremia…and suggest that complete eradication of replication-competent HIV 
from the body may not necessary for long-term remission from the effects of HIV and the 
suppression of viral replication in the absence of ART” (188). This statement has shifted the 
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authors initial opinion that ECs are not necessarily the most suitable model for functional cure 
to actually confirm that ECs do indeed hold important clues on how to achieve sustained long-
term viral control without ART. This indeed demonstrates, despite several studies on this 
unique group of subjects, the importance of the continued study of the characteristic features 
of ECs and defining the protective factors contributing to sustained control as well as factors 
associated with disease progression, in the context of translating mechanism of viral control to 
future cure strategies.  
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